Background-Atrial fibrillation (AF) is an important risk factor for stroke and is common among elderly patients undergoing transcatheter aortic valve implantation. The aim of this study was to assess the impact of AF on clinical outcomes among patients undergoing transcatheter aortic valve implantation.
A trial fibrillation (AF) is the most common arrhythmia in the general population characterized by uncoordinated electric activation of the atria. 1 Its prevalence increases with age ranging from 0.1% among patients <55 years to >9.0% in patients aged ≥80 years. 2 Because of the high prevalence of this rhythm disorder in the elderly population as well as similar risk factors for AF and severe degenerative aortic stenosis, both conditions may coexist in ≤50% of patients. 3, 4 AF importantly affects cardiovascular physiology attributable to loss of atrioventricular synchrony and irregularity of ventricular contraction resulting in reduced cardiac output and increased filling pressures, 5 which may be further accentuated in the presence of severe aortic stenosis and myocardial hypertrophy. Conversely, left ventricular outflow obstruction attributable to aortic stenosis results in left ventricular hypertrophy and diastolic dysfunction, which itself may precipitate AF attributable to increased left atrial pressures.
AF has an important impact on cardiovascular morbidity and mortality. Population-based studies indicate an increased risk of stroke and systemic embolism as well as impaired long-term survival of individuals with AF compared with those with normal sinus rhythm. 6, 7 Among patients with severe aortic stenosis and reduced left ventricular function undergoing surgical aortic valve replacement (SAVR), AF has been associated with an increased risk of perioperative and long-term adverse events. 8 Moreover, AF is an independent predictor for late adverse cardiac and cerebrovascular events, including congestive heart failure, stroke, and mortality after SAVR. 9 Transcatheter aortic valve implantation (TAVI) has become the treatment of choice among inoperable patients with severe, symptomatic aortic stenosis and is a treatment alternative to SAVR among high-risk elderly patients. However, little is known regarding the impact of preexisting and new-onset AF among those patients undergoing TAVI for treatment of severe aortic stenosis. We, therefore, compared the long-term clinical outcomes between patients with and without AF undergoing TAVI enrolled in a single center prospective registry and followed through 1 year.
Methods

Patient Population
Between August 2007 and October 2011, a total of 389 high-risk elderly patients with symptomatic severe aortic stenosis were included in a prospective single center registry (Bern TAVI Registry). Patients underwent TAVI with the self-expandable Medtronic CoreValve (Medtronic, Minneapolis, MN) and the balloon-expandable Edwards Sapien transcatheter heart valve (Edwards LifeSciences, Irvine, CA) via the transfemoral, the transapical, and the subclavian access routes, as previously described. 10 After the procedure, patients were either admitted to the intensive care or coronary care unit and monitored during the first 48 hours after the intervention for rhythm disturbances and other adverse events. After this, patients were transferred to the general ward, and rhythm disturbances were recorded with continuous monitoring using telemetric ECG surveillance. All patients were treated with acetylsalicylic acid 100 mg per day indefinitely and clopidogrel 75 mg per day for 6 months. Among patients with an indication for oral anticoagulation, a vitamin K antagonist was combined with either acetylsalicylic acid or clopidogrel alone.
The study complied with the Declaration of Helsinki, and the registry was approved by the local ethics committee. All patients provided written informed consent to participate in the registry with prospective follow-up assessment.
Data Collection
All patients were evaluated for the presence and absence of AF, including a systematic review of all electrocardiograms at the time of admission, during the hospitalization and at discharge. Moreover, any new episode of AF, irrespective of the requirement of a therapeutic intervention or early spontaneous conversion into normal sinus rhythm, during the hospitalization was recorded. Because atrial flutter is another supraventricular rhythm that may coexist or precede AF, we assigned patients with atrial flutter to the AF study group.
Adverse events were assessed in hospital, and regular clinical follow-up was performed for 30 days and 12 months by means of a clinical in-hospital visit or a standardized telephone interview. All suspected events were adjudicated by an unblinded clinical event committee consisting of interventional cardiologists and cardiac surgeons.
Definitions
For the purpose of this study, patients were categorized into 2 groups: (1) patients with AF specified according to the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society classification 11 -paroxysmal (recurrent episodes of AF that terminate spontaneously within 7 days), persistent (recurrent episodes with a duration of >7 days), and permanent AF (ongoing longterm episode) or new-onset AF after the TAVI intervention; and (2) patients without AF. CHADS 2 scores and CHA 2 DS 2 -VASC scores were calculated for patients with AF.
Clinical adverse events were adjudicated according to the Valve Academic Research Consortium (VARC) end point definitions, described in detail elsewhere. 12 The prespecified primary end point of the study was all-cause mortality.
Statistical Analysis
Baseline clinical and procedural characteristics, as well as followup data, were entered into a dedicated database, held at an academic clinical trials unit (Cardiobase, CTU Bern, Bern University Hospital) responsible for central data audits and maintenance of the database. Statistical analyses were performed by a statistician of an academic clinical trials unit (D.H., P.J.) using Stata 12 (StataCorp LP, College Station, TX). Continuous variables are presented as mean±SD and are compared by means of unpaired t tests. Categorical data are expressed as frequencies and percentages and are compared using χ 2 and Fisher exact tests. Survival estimates were reconstructed using the Kaplan-Meier method at 12-month follow-up. Outcomes in the AF group (raw counts [%]) were compared using Cox regression analysis censoring at last follow-up or death, respectively (crude). The corresponding hazard ratios (HR, 95% confidence interval [CI]) with probability values are also given. The proportional hazards assumption was tested using Schoenfeld residuals. Endpoints with zero events were presented with continuity corrected risk ratios (and 95% CI), but no attempt was made to estimate risk ratio comparing 1 event versus 0 event. The adjusted Cox regression analyses (inverse probability of treatment weight [IPTW]) of end points at 12 months were performed by weighing each patient's effect with the IPTW, where the treatment is AF (coded yes=1 and no AF=0). The propensity score was calculated by including all baseline characteristics affecting AF with a P value of <0.2 or affecting overall death at 12 months with a P value of <0.2. Bleeding events up to 12-month follow-up comparing AF groups were analyzed using Poisson regression with robust error variances and reported as counts (%) with risk ratio (95% CI). We prespecified crude analyses comparing the different types of AF versus no AF. We prespecified stratified outcome IPTW analyses, comparing the group of patients with AF with those without AF according to age (cutoff point 80 years of age), sex, diabetes mellitus, renal failure (cutoff point glomerular filtration rate <60 mL/ min per 1.73 m 2 ), and ejection fraction (cutoff point left ventricular ejection fraction, 40%). In this stratified analysis, we tested for the difference between patients with AF and without AF in each subgroup separately (eg, EF <40 and >40), and we tested whether the interaction between the subgroup and the AF group was significant
WHAT IS KNOWN
• Atrial fibrillation is the most frequent arrhythmia and its prevalence increases with age.
• Because of similar risk factors, atrial fibrillation and degenerative aortic stenosis may coexist in ≤50% of patients.
• Atrial fibrillation has an important impact on cardiovascular morbidity and mortality and is an independent predictor for adverse cardiac and cerebrovascular events after surgical aortic valve replacement.
WHAT THE STUDy ADDS
• Atrial fibrillation is observed in up to one third of high-risk patients with symptomatic, severe aortic stenosis undergoing transcatheter aortic valve implantation.
• Atrial fibrillation is associated with a 2-fold increased risk of all-cause and cardiovascular mortality among patients undergoing transcatheter aortic valve implantation at 1-year follow-up.
• Among patients with atrial fibrillation and severe aortic stenosis undergoing transcatheter aortic valve implantation, the CHA 2 DS 2 -VASC score directly correlates with the risk of all-cause mortality.
in the model containing both subgroups (eg, EF group × AF group interaction). All P values and CIs are 2-sided. A P value <0.05 was considered statistically significant. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the article as written.
Results
Patient Population
Among 389 consecutive patients undergoing TAVI for treatment of degenerative aortic valve stenosis, AF was recorded in 131 patients (33.7%). The mean CHA 2 DS 2 -VASC score amounted to 4.5±1.2 with 96% of patients with AF having a score >3. AF was documented before the procedure (preexisting) in 104 patients (26.7%) and was classified as paroxysmal in 26 (25.0%), persistent in 8 (7.7%), and permanent in 70 (67.3%) patients. New-onset AF was observed in 27 patients (6.9%) within 11±6 days after TAVI. Baseline clinical characteristics of patients undergoing TAVI are summarized in Table 1 . Previous revascularization procedures were less common among TAVI patients with AF compared with patients without AF (coronary artery bypass grafting: 12% versus 22%; P=0.03; percutaneous coronary intervention: 18% versus 28%; P=0.03). Antithrombotic treatment more frequently included oral anticoagulation with a vitamin K antagonist among TAVI patients with (52%) than without AF (15%; P<0.001).
Procedural Results
Procedural characteristics and results are shown in Table  2 . The preferred treatment strategy was the transfemoral access route (79%), and patients were treated either with the Medtronic CoreValve (58%) or the Edwards Sapien (42%) transcatheter heart valve prosthesis. There was no significant difference for any of the procedural characteristics, including procedure time, type of anesthesia, access route, and revascularization strategy among TAVI patients with and without AF.
Clinical Outcomes
Clinical outcomes through 1 year are summarized in Table  3 . All-cause mortality was higher among patients with AF (30.9%) compared with those without AF (13.9%; HR, 2.36; 95% CI, 1.43-3.90; P=0.0008), which was mainly attributable to a higher cardiac mortality (23.4% versus 9.7%; HR, 2.37; 95% CI, 1.32-4.26; P=0.004). The composite of all-cause death, major stroke, or myocardial infarction was more common among patients with AF (32.2%) than without AF (18.6%; HR, 1.80; 95% CI, 1.14-2.85; P=0.01), whereas there were no differences with respect to myocardial infarction (1.5% versus 1.5%; HR, 1.53; 95% CI, 0.26-9.19; P=0.64), major stroke (3.9% versus 5.1%; HR, 0.67; 95% CI, 0.23-1.96; P=0.47), or transient ischemic attack (0% versus 0.6%).
The increased risk of death among patients with AF as compared with those without AF was more pronounced for preexisting (HR, 2.50; 95% CI, 1.48-4.23; P=0.00061) than for new-onset AF (HR, 1.91; 95% CI, 0.78-4.68; P=0.16) at 1 year (Table I in the online-only Data Supplement) ( Figure 1 ). All-cause mortality was increased for any type of AF including permanent (HR, 2.47; 95% CI, 1.40-4.38; P=0.002), persistent (HR, 3.60; 95% CI, 1.10-11.78; P=0.034), and paroxysmal AF (HR, 2.88; 95% CI, 1.37-6.05; P=0.005) (Figure 2 ). In stratified analyses, the increased mortality risk among patients with AF as compared with those without AF was consistent across major subgroups, including age, diabetes mellitus, renal function, coronary artery disease, and left ventricular ejection fraction (Figure 3 ). Among patients with AF, the risk of death at 1 year correlated with the CHA 2 DS 2 -VASC score and was highest in the group of patients with a CHA 2 DS 2 -VASC score of >6 (HR, 4.12; 95% CI, 2.07-8.20; P=0.00039) (Figure 4 ). Table II in the online-only Data Supplement). The majority of patients without AF received dual antiplatelet therapy with aspirin and clopidogrel (84%) at the time of hospital discharge, whereas few patients received an individualized treatment approach with either vitamin K antagonist monotherapy (2%), combination of either aspirin and vitamin K antagonist (5%), or clopidogrel and vitamin K antagonist (4%). Patients with AF received dual antiplatelet therapy in 31%, a combination of clopidogrel and vitamin K antagonist in 19%, aspirin and vitamin K antagonist in 20%, or vitamin K antagonist monotherapy in 14% of cases at the time of hospital discharge. The differences in antithrombotic treatment between patients with AF and without AF were sustained at 30 days and 1 year of follow-up (P<0.001).
Discussion
The present study investigating clinical outcomes of patients with symptomatic severe aortic stenosis and concomitant AF undergoing TAVI has the following main findings:
• AF is common among high-risk elderly patients with symptomatic severe aortic stenosis undergoing TAVI. • AF is associated with a >2-fold increased risk of all-cause and cardiovascular mortality at 1 year in this patient population. • AF confers an increased risk of mortality irrespective of type of AF among TAVI patients. • The CHA 2 DS 2 -VASC score among patients with AF and severe aortic stenosis undergoing TAVI directly correlates with the risk of death.
The prevalence of AF in patients with symptomatic severe aortic stenosis is high and amounted to 34% in this elderly patient population. AF may be the direct result of heart failure precipitated by aortic stenosis attributable to increased atrial pressures and atrial dilatation leading to atrial fibrosis and regional conduction abnormalities which beget AF. Conversely, AF may impair symptoms of heart failure among patients with severe aortic stenosis attributable to loss of atrioventricular synchrony, the fast and irregular ventricular response, and sympathetic activation leading to therapeutic intervention. 16 the mechanisms leading to the arrhythmia after minimal-invasive catheter-based aortic valve implantation are less well understood. Amat-Santos et al 17 investigated the impact of new-onset AF among 138 high-risk patients without a history of previous AF undergoing TAVI and, therefore, excluded a priori patients with preexisting AF. In this study, new-onset AF was observed in up to one third of patients as compared with 7% in the present study and was associated with a higher rate of cerebrovascular events, but not death, during the follow-up period.
In the general population, AF is estimated to increase the risk of death 1.5-fold among men and 1.9-fold among women. 6, 18 Among patients with heart failure and reduced left ventricular function, new-onset AF has been identified as an independent predictor of mortality and long-term follow-up of the Framingham cohort, suggesting that patients with AF have a deleterious outcome. 19 In the present study of elderly patients undergoing TAVI, patients with AF experienced worse clinical outcome with respect to all-cause death and cardiovascular mortality compared with patients without AF. These findings are supported by a recent multicenter study evaluating prognostic factors and long-term outcomes after TAVI. In this study, chronic AF emerged as 1 of the predictors of late mortality with a 1.4-fold increased risk for all-cause mortality. 20 This observation among patients undergoing TAVI is in accordance with outcomes after SAVR in patients with preexisting AF and reduced left ventricular function, where AF is associated with an ≈8-fold increased risk of mortality 8 compared with patients without AF during short-and long-term follow-up. 9 Multiple reasons might be responsible for this. In most cases, the development of AF is an expression of advanced heart disease with structural remodeling and myocardial fibrosis, 21 which by accelerating the process of cardiac senescence may increase cardiovascular mortality. Moreover, the loss of atrioventricular synchrony and the variation in ventricular cycle length lead to impaired ventricular filling, reduced cardiac output, and increased afterload, which are hemodynamic factors known to adversely affect clinical outcomes among heart failure patients. Of note, we did not observe differences in rates of stroke or systemic embolism between patients with and without AF in the present study as potential explanation for differences in mortality. Although we cannot exclude the benefit of appropriately chosen antithrombotic therapy, it is more likely that the majority of strokes occurred during the peri-interventional period and, therefore, represented adverse events related to the procedure potentially camouflaging the risk of stroke inherent to AF. 22 Patients with AF experienced an increased risk of death irrespective of the type of AF, including permanent (HR, 2.47; 95% CI, 1.40-4.38; P=0.002), persistent (HR, 3.60; 95% CI, 1.10-11.78; P=0.034), and paroxysmal AF (HR, 2.88; 95% CI, 1.37-6.05; P=0.005) in the present study. The European Heart Survey on AF observed the highest rate of death among patients with permanent AF, although mortality remained substantial among patients with first onset of AF. 23 In the French Etude en Activité Libérale de la Fibrillation Auriculaire (ALFA) study, the type of AF was not predictive of mortality and risk of systemic embolism. Similarly, the risk of stroke has been shown as high for paroxysmal as for persistent and permanent AF in previous cohort studies. 24 AF constitutes a major risk factor for cardioembolic ischemic events that are associated with significant disability, partial or total loss of independence in everyday life activities, and a high rate of mortality. 22 The recommended antithrombotic therapy is able to reduce these events, while increasing the risk for bleeding especially in this elderly patient population. 25 The CHADS 2 -and more recently the CHA 2 DS 2 -VASC score provide a reliable risk stratification for cerebrovascular events in patients with AF. 26 The CHA 2 DS 2 -VASC score was a marker of impaired prognosis in the present study with a gradual increase in the risk of death with increasing CHA 2 DS 2 -VASC scores (Figure 4) . The predictive ability of the CHA 2 DS 2 -VASC score in terms of death in patients with AF has been recently confirmed in a large patient population from the Prospective Danish Diet, Cancer and Health cohort study. 27
Limitations
Several limitations need to be acknowledged, when interpreting the results of this study. First, the study population is based on the experience of a single, tertiary care center, and the results may not be applicable to other centers with different procedural experience, as well as device and patient selection. Second, the assessment of AF was based on preprocedural ECG evaluation and the review of patient charts, including past medical history as well as previous reports from referring cardiologists and general practitioners. Despite careful and complete assessment of patient data, only symptomatic and apparent episodes of AF have been detected, leaving a small proportion of patients with asymptomatic, paroxysmal AF which may have been undetected. Finally, because of the preprocedural evaluation algorithm at our institution to perform transesophageal echocardiography rather than transthoracic echocardiography, we are unable to include reliable data on left atrial size, myocardial mass, or other specific hemodynamic data in our analysis.
Conclusion
AF is common among high-risk patients with severe aortic stenosis undergoing TAVI and is associated with a >2-fold increased risk of all-cause and cardiovascular mortality, irrespective of the type of AF. The gradient of risk directly correlates with the CHA 2 DS 2 -VASC score.
